AVImark vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Widely deployed on-premise veterinary PMS now owned by Covetrus and integrated with IDEXX reference labs. Large installed base of independent US small-animal practices that adopted AVImark as the de facto standard before cloud alternatives;
About
AVImark is a veterinary practice management software system that has been widely deployed in independent veterinary practices across the United States for decades, and is currently owned by Covetrus—the animal health technology and distribution company formed from the combination of Henry Schein Animal Health and Vets First Choice, which was subsequently acquired by IDEXX Laboratories. AVImark's strength lies in its deep penetration of the independent small-animal practice market, where it became the de facto standard system for many practices that adopted practice management software in the 1990s and 2000s. The software provides scheduling, medical records, invoicing, inventory management, and client communication in an on-premise Windows-based system that has been continuously developed and supported through multiple ownership transitions.\n\nAVImark's integration with IDEXX's reference laboratory and diagnostic services is a significant feature of the current product, allowing practices to send laboratory orders electronically and receive results directly within the AVImark patient record. This IDEXX connectivity is particularly valuable for practices that are already IDEXX lab customers and want to reduce manual result transcription. Covetrus has also integrated AVImark with its online pharmacy and prescription management services, creating a connected ecosystem that links practice management, diagnostics, and medication dispensing for AVImark-using clinics.\n\nAVImark faces competitive pressure from cloud-native veterinary practice management systems including Shepherd, ezyVet, and Digitail that offer more modern user experiences, mobile accessibility, and frequent feature updates without requiring on-premise hardware. Covetrus has been investing in a cloud migration path for AVImark customers while also offering its newer Pulse platform as a cloud-native alternative for practices ready to move off legacy on-premise systems. The installed base of AVImark users represents a significant asset for Covetrus but also a long-term migration and retention challenge as the industry shifts toward cloud deployment.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.